Stephen Squinto, Chairman of the Board
Stephen Squinto is a Venture Partner with OrbiMed who brings over 25 years of experience in the biotechnology industry. Dr. Squinto was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its Executive Vice President and Chief Global Operations Officer. Prior to 2013, he was Alexion’s Global Head of Research and Development. From 1988 to 1992, Dr. Squinto held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work. Dr. Squinto received his B.A. in Chemistry and Ph.D. in Biochemistry and Biophysics from the Loyola University of Chicago.
Nissim Darvish is a Senior Managing Director of Orbimed Venture Capital. Nissim is a veteran of the life science industry, with fifteen years of experience covering medical technology development, corporate leadership, and investment management.
Nissim spent eight years with Pitango, where he was a general partner managing investments in life sciences.
Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents, authored over 20 publications and received eight prizes and awards.
Jason Camm is the Chief Medical Officer at Thiel Capital. He co-leads a team focused on breakthrough life science investments and has experience in medical technologies, biopharmaceuticals, corporate leadership and investment management.
Jason currently sits on the board of numerous biotechnology companies as well as the board of Tufts University Friedman school.
David Ben Ami,
David Ben Ami is serving as the Executive Investment Director of SBI JI Innovation Advisory Ltd. He has more than 25 years of experience with activities in management, business development, corporate strategy and investments in the life sciences industry.
David is also Managing Partner at Corundum Open Innovation Fund which he co-founded in 2016. Prior to his current positions David held other key positions related to the health industry. He was the Founder and Executive Chairman of NASDAQ listed company Macrocure Ltd. from 2008 to 2016, ֲ CEO of NVR Labs Ltd. from 2005 to 2010, Israeli Country Manager for Boston Scientific from 2003 to 2005, and the Director of Business Development for Teva Israel and Teva Medical from 1999 through 2002.
David current and past Board positions include companies such as Immunobrain Checkpoint Inc., Entera Bio, Novolog Ltd, Degania Medical Ltd., Biocell Ltd., Meytav Technology Incubator, Hairstetics Ltd., VVT Medical Ltd., Contipi Medical Ltd. and others
Adi Mor is the co-founder and CEO of ChemomAb since 2011. Adi has extensive knowledge and experience in the fields of immunology, autoimmune and inflammatory diseases and a wide experience in designing, promoting and patenting a novel class of monoclonal antibodies to treat inflammatory and cancer diseases. Adi completed her Ph.D. in Immunology from the Tel Aviv University in the Department of Neurobiochemistry and is a lead author of multiple publications in scientific journals in the fields of immunology and inflammatory disorders.